Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers
暂无分享,去创建一个
Audrey Kauffmann | Jianjun Yu | Yumin Dai | Mika Lindvall | J. Yu | M. Lindvall | A. Kauffmann | C. Fanton | Jiong Lan | P. Feucht | Stephen Basham | Jianjun Yu | J. Holash | C. Bellamacina | P. Drueckes | M. Burger | C. Fritsch | J. Trappe | Christopher Wilson | Jocelyn Holash | Cornelia Bellamacina | Matthew T Burger | Pablo D Garcia | Wooseok Han | Richard Zang | Tiffany Tsang | T. Zavorotinskaya | Yumin Dai | Jamie Narberes | Peter Drueckes | Joerg Trappe | Jiong Lan | Jing Lu | Tatiana Zavorotinskaya | Xiao-Hong Niu | Joseph Castillo | Yingyun Wang | John L Langowski | Min Chen | Christie Fanton | Marjorie Ison | Stephen Basham | Julie Chan | Michael Doyle | Paul Feucht | Robert Warne | Jamie Narberes | Tiffany Tsang | Christine Fritsch | Estelle Pfister | Christopher Wilson | Gisele Nishiguchi | J Alex Aycinena | Richard Zang | R. Warne | Yingyun Wang | J. Langowski | G. Nishiguchi | J. Chan | Marjorie Ison | Jing Lu | Pablo D. Garcia | Mike Doyle | Min Chen | W. Han | Joseph Castillo | Xiaohong Niu | E. Pfister | J. A. Aycinena
[1] Chris Harbron,et al. RefPlus: an R package extending the RMA Algorithm , 2007, Bioinform..
[2] Carmen Blanco-Aparicio,et al. The PIM Family of Serine/Threonine Kinases in Cancer , 2014, Medicinal research reviews.
[3] A. Ferguson,et al. Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases. , 2012, Bioorganic & medicinal chemistry letters.
[4] G. Roboz. Novel approaches to the treatment of acute myeloid leukemia. , 2011, Hematology. American Society of Hematology. Education Program.
[5] T. Meeker,et al. Cloning and characterization of the human PIM‐1 gene: A putative oncogene related to the protein kinases , 1987, Journal of cellular biochemistry.
[6] Michelle S. Miller,et al. Quantitative expression profiling guided by common retroviral insertion sites reveals novel and cell type specific cancer genes in leukemia. , 2008, Blood.
[7] M. Nawijn,et al. For better or for worse: the role of Pim oncogenes in tumorigenesis , 2011, Nature Reviews Cancer.
[8] N. Sonenberg,et al. mTOR, translation initiation and cancer , 2006, Oncogene.
[9] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[10] J. Mestan,et al. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. , 2010, Biochimica et biophysica acta.
[11] A. Jemal,et al. Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.
[12] Stefan Knapp,et al. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers , 2010, Haematologica.
[13] Jun Li,et al. Structural Basis of Constitutive Activity and a Unique Nucleotide Binding Mode of Human Pim-1 Kinase* , 2005, Journal of Biological Chemistry.
[14] Jianjun Yu,et al. Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation. , 2013, Blood.
[15] J. Downing,et al. Mouse models of human AML accurately predict chemotherapy response. , 2009, Genes & development.
[16] V. Danilenko,et al. Fighting tumor cell survival: advances in the design and evaluation of Pim inhibitors. , 2010, Current medicinal chemistry.
[17] T. Morwick. Pim kinase inhibitors: a survey of the patent literature , 2010, Expert opinion on therapeutic patents.
[18] Yu Ding,et al. Structure Guided Optimization, in Vitro Activity, and in Vivo Activity of Pan-PIM Kinase Inhibitors. , 2013, ACS medicinal chemistry letters.
[19] F. Giles,et al. Targeting PIM kinase activity significantly augments the efficacy of cytarabine , 2012, British journal of haematology.
[20] R. Myers,et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data , 2005, Nucleic acids research.
[21] A. Kraft,et al. The PIM-2 Kinase Phosphorylates BAD on Serine 112 and Reverses BAD-induced Cell Death* , 2003, Journal of Biological Chemistry.
[22] A. Berns,et al. Proviral tagging in E mu‐myc transgenic mice lacking the Pim‐1 proto‐oncogene leads to compensatory activation of Pim‐2. , 1995, The EMBO journal.
[23] E. Newsholme,et al. The contents of adenine nucleotides, phosphagens and some glycolytic intermediates in resting muscles from vertebrates and invertebrates. , 1975, The Biochemical journal.
[24] J. Arthur,et al. Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL , 2006, BMC Cell Biology.
[25] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[26] Jos Jonkers,et al. Mice Deficient for All PIM Kinases Display Reduced Body Size and Impaired Responses to Hematopoietic Growth Factors , 2004, Molecular and Cellular Biology.
[27] A. Kraft,et al. Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is mediated by Pim-1. , 2013, Cancer research.
[28] Jos Jonkers,et al. MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer , 2007, Nature Genetics.
[29] A. Berns,et al. Predisposition to lymphomagenesis in pim-1 transgenic mice: Cooperation with c-myc and N-myc in murine leukemia virus-induced tumors , 1989, Cell.
[30] Wim Quint,et al. Murine leukemia virus-induced T-cell lymphomagenesis: Integration of proviruses in a distinct chromosomal region , 1984, Cell.
[31] Anton Berns,et al. High-throughput retroviral tagging to identify components of specific signaling pathways in cancer , 2002, Nature Genetics.
[32] P. Koskinen,et al. Pim‐1 kinase promotes inactivation of the pro‐apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site , 2004, FEBS letters.